A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
Key facts
- Who runs it
- Ionis Pharmaceuticals, Inc.
- Where
- Boca Raton, Columbus, Council Bluffs, Evanston, Flint, Gurnee, Lansdale, Las Vegas, Lincoln, Little River, Louisville, Manassas, Mesquite, Miami, Montclair, New Port Richey, Norfolk, Rapid City, Tullahoma, and Winter Park, United StatesSee the 21 sitesAlso in 1 other country, 3 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 154 people enrolled
- Started
- 9 May 2022
- Ended
- 21 Dec 2023
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Olezarsen
- Placebo
- Record updated
- 23 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Aged ≥ 18 years at the time of informed consent
- Fall into at least 1 of the following groups (a or b):; Hypertriglyceridemia with fasting TG ≥ 150 mg/dL (1.69 millimoles per liter [mmol/L]) and < 500 mg/dL (5.65 mmol/L) with either clinical diagnosis of atherosclerotic cardiovascular disease (ASCVD) or at increased risk for ASCVD; Severe hypertriglyceridemia with fasting TG ≥ 500 mg/dL (5.65 mmol/L)
- Participants must be on standard-of-care (SOC), lipid-lowering medications per local guidelines
- Participants must be willing to comply with diet and lifestyle recommendations as able
Who cannot take part
- Acute coronary syndrome or stroke/transient ischemic attack (TIA) within 6 months prior to Screening
- Major surgery, peripheral revascularization, or non-urgent percutaneous coronary intervention (PCI) within 3 months prior to Screening, or upcoming planned major surgery or major procedure (e.g., arterial revascularization) during the course of the study
- Active pancreatitis within 4 weeks prior to Screening
- Diabetes with any of the following:; Newly diagnosed within 12 weeks of screening; Hemoglobin A1C (HbA1c) ≥ 9.5% at Screening; Change in basal insulin regimen > 20% within 3 months prior to Screening; For participants with type 1 diabetes: episode of diabetic ketoacidosis, or ≥ 3 episodes of severe hypoglycemia within 6 months prior to Screening
Where in United States
Also in 1 other country, 3 sites
- Excel Medical Clinical Trials, LLCBoca Raton, United States
- IACT HealthColumbus, United States
- West Broadway ClinicCouncil Bluffs, United States
- Evanston Premier Healthcare ResearchEvanston, United States
- Aa Mrc LlcFlint, United States
- Clinical Investigation SpecialistGurnee, United States
- Green and Seidner Family Practice AssociatesLansdale, United States
- Clinical Research of South NevadaLas Vegas, United States
- Palm Research Center IncLas Vegas, United States
- Clinical Trials ResearchLincoln, United States
- Main Street Physicians Care WaterwayLittle River, United States
- Louisville Metabolic and Atherosclerosis Research Center (L-MARC)Louisville, United States
- Manassas Clinical Research CenterManassas, United States
- Southern Endocrinology AssociatesMesquite, United States
- De La Cruz Research CenterMiami, United States
- Catalina Research Institute, LLCMontclair, United States
- Suncoast Clinical Research, Inc.New Port Richey, United States
- York Clinical Research LLCNorfolk, United States
- Health ConceptsRapid City, United States
- Tennessee Center for Clinical TrialsTullahoma, United States
- Research Physicians Network AllianceWinter Park, United States
About the trial
What the trial wants to find out
The purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in fasting TG. Other objectives were to evaluate the effect of olezarsen on percent change in fasting apolipoprotein C-III (apoC-III), very low-density lipoprotein cholesterol (VLDL-C), remnant cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), HDL-C, total cholesterol (TC), apolipoprotein B (apoB), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein A-1 (apoA-1).
The 3 groups in the trial
- PlaceboPlacebo, for comparison
Participants received olezarsen-matching placebo, as a single subcutaneous (SC) injection, once every 4 weeks for 53 weeks treatment period.
- Olezarsen 50 mgTreatment being tested
Participants received olezarsen 50 mg, as a single 0.5 milliliters (mL) SC injection, once every 4 weeks for 53 weeks treatment period.
Treatment: Olezarsen
- Olezarsen 80 mgTreatment being tested
Participants received olezarsen 80 mg, as a single 0.8 mL SC injection, once every 4 weeks for 53 weeks treatment period.
Treatment: Olezarsen
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-blind, Placebo-Controlled, Phase 2b Study of ISIS 678354 in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
- Publications
- Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.The New England journal of medicine, 2024
- Record updated
- 23 April 2026